Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Aug 24, 2023
0
3